behind the ongoing product supply shortages in the US and incentivization of generic drug companies to manufacture the same. It however remains to be seen how this plays out in terms of improving economic dynamics for generic companies. The following are the key highlights of the USFDA release. The US agency has been able to significantly curtail number of drugs with shortages since the implementation of the FDASIA Act in 2012. From ~251 product shortages in 2011 it has come down to ~39 in 2017. However, what is notable is that the USFDA has for the first time acknowledged that existing methods & procedures alone cannot further slash the...